We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-64.00 | -0.60% | 10,678.00 | 10,688.00 | 10,690.00 | 10,780.00 | 10,674.00 | 10,756.00 | 1,773,970 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 27.83 | 165.72B |
By Denise Roland
AstraZeneca PLC has appointed Genentech's Sean Bohen as executive vice president of Global Medicines Development and chief medical officer, filling a key research and development role that was left vacant with the sudden departure of Briggs Morrison in June.
The U.K.-based drug maker said Dr. Bohen, who was President of Early Development at Genentech, a division of Switzerland's Roche AG, will join the company on Sept. 15.
He will take on responsibility for the development of AstraZeneca's pipeline of drugs through clinical trials to regulatory approval, the company said in a statement. This will place Dr. Bohen at the heart of Astra's strategy to nearly double its annual revenue to $45 billion by 2023, a goal which depends on the success of its new and upcoming drugs. This target was part of Mr. Soriot's defense against an unsolicited acquisition approach from rival Pfizer Inc. last year.
Chief Executive Pascal Soriot said Dr. Bohen's "impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients."
Dr. Bohen was also previously an oncology specialist at Stanford University School of Medicine. Cancer medicines form a key part of Astra's growth plans, with oncology drugs expected to account for one quarter of its long-term revenue target.
His predecessor Dr. Morrison exited Astra to become chief executive of Syndax Pharmaceuticals, a closely-held biotech company developing a compound in immuno-oncology, a hot new therapy area that harnesses the immune system to fight tumors.
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 24, 2015 04:52 ET (08:52 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions